Changes in renin-angiotensin-aldosterone system during cardiac remodeling after mitral valvuloplasty in dogs.
angiotensin II
biomarker
cardiac recovery
cardiac reverse remodeling
mitral valve repair
plasma renin activity
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
07
12
2021
received:
20
05
2021
accepted:
13
12
2021
pubmed:
8
1
2022
medline:
1
4
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
Information regarding changes in renin-angiotensin-aldosterone system (RAAS) during cardiac remodeling after mitral valvuloplasty (MVP) in dogs remains lacking. To assess the longitudinal effects of MVP on circulating RAAS activity. Eight client-owned dogs receiving MVP for myxomatous mitral valve disease (MMVD). This is a cohort study. Plasma renin activity (PRA), angiotensin II (AT2), aldosterone (PAC), blood urea nitrogen (BUN), and creatinine concentrations, were measured in these dogs before (baseline) and at 3 consecutive monthly follow-ups (Post-1M, Post-2M, Post-3M). Echocardiography was concomitantly used to assess the process of cardiac recovery after MVP. The echocardiography revealed a significant decrease in LVIDDN, LA/Ao, FS, E velocity, E/A, E' sep, S' lat, E' lat, and A' lat after MVP compared with baseline (P < .05). There was a significant reduction in the PRA (2.45, 3.05, 2.74 vs 8.8 ng/mL/h; P = .002), AT2 (466, 315, 235 vs 1200 pg/mL; P = .009), and PAC (39.88, 47, 54.62 vs 179.5 pg/mL; P = .01), respectively at Post-1M, Post-2M, Post-3M compared to the baseline. Additionally, BUN and creatinine concentrations decreased from Post-1M. The RAAS variables showed significant, weak to moderate, relationship with selected echocardiographic variables. Mitral valvuloplasty contributes to decreased RAAS activity in MMVD dogs, which paralleled the process of cardiac reverse remodeling up to Post-3M. This information facilitates formulating strategies to optimize clinical outcomes for dogs after MVP.
Sections du résumé
BACKGROUND
BACKGROUND
Information regarding changes in renin-angiotensin-aldosterone system (RAAS) during cardiac remodeling after mitral valvuloplasty (MVP) in dogs remains lacking.
HYPOTHESIS/OBJECTIVES
OBJECTIVE
To assess the longitudinal effects of MVP on circulating RAAS activity.
ANIMALS
METHODS
Eight client-owned dogs receiving MVP for myxomatous mitral valve disease (MMVD).
METHODS
METHODS
This is a cohort study. Plasma renin activity (PRA), angiotensin II (AT2), aldosterone (PAC), blood urea nitrogen (BUN), and creatinine concentrations, were measured in these dogs before (baseline) and at 3 consecutive monthly follow-ups (Post-1M, Post-2M, Post-3M). Echocardiography was concomitantly used to assess the process of cardiac recovery after MVP.
RESULTS
RESULTS
The echocardiography revealed a significant decrease in LVIDDN, LA/Ao, FS, E velocity, E/A, E' sep, S' lat, E' lat, and A' lat after MVP compared with baseline (P < .05). There was a significant reduction in the PRA (2.45, 3.05, 2.74 vs 8.8 ng/mL/h; P = .002), AT2 (466, 315, 235 vs 1200 pg/mL; P = .009), and PAC (39.88, 47, 54.62 vs 179.5 pg/mL; P = .01), respectively at Post-1M, Post-2M, Post-3M compared to the baseline. Additionally, BUN and creatinine concentrations decreased from Post-1M. The RAAS variables showed significant, weak to moderate, relationship with selected echocardiographic variables.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Mitral valvuloplasty contributes to decreased RAAS activity in MMVD dogs, which paralleled the process of cardiac reverse remodeling up to Post-3M. This information facilitates formulating strategies to optimize clinical outcomes for dogs after MVP.
Identifiants
pubmed: 34994485
doi: 10.1111/jvim.16346
pmc: PMC8965262
doi:
Substances chimiques
Aldosterone
4964P6T9RB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
397-405Informations de copyright
© 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Am Heart J. 2018 Dec;206:30-50
pubmed: 30300847
Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S67-76
pubmed: 22120095
Open Vet J. 2017;7(4):328-331
pubmed: 29201662
J Vet Intern Med. 2021 Jan;35(1):22-32
pubmed: 33368659
J Am Heart Assoc. 2020 Sep 15;9(18):e016911
pubmed: 32893727
J Am Soc Echocardiogr. 2012 Oct;25(10):1099-105
pubmed: 22898243
Circulation. 2005 Jul 19;112(3):364-74
pubmed: 15998679
J Vet Intern Med. 1995 Sep-Oct;9(5):328-31
pubmed: 8531178
J Vet Intern Med. 2019 May;33(3):1127-1140
pubmed: 30974015
J Vet Intern Med. 2019 Jul;33(4):1571-1584
pubmed: 31254308
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):687-697
pubmed: 32104977
J Vet Intern Med. 2022 Mar;36(2):397-405
pubmed: 34994485
J Am Coll Cardiol. 2007 Mar 20;49(11):1166-74
pubmed: 17367660
Clin Chem. 2018 Mar;64(3):597-608
pubmed: 29138270
J Vet Med Sci. 2010 Jan;72(1):13-8
pubmed: 19893284
J Vet Intern Med. 2020 Jan;34(1):139-144
pubmed: 31729111
Hypertension. 2019 Aug;74(2):285-294
pubmed: 31230551
J Vet Intern Med. 2004 May-Jun;18(3):311-21
pubmed: 15188817
Eur Heart J. 2009 Apr;30(7):805-12
pubmed: 19223317
Int J Cardiol. 2014 Dec 15;177(2):680-2
pubmed: 25449483
Circulation. 1995 Feb 15;91(4):1022-8
pubmed: 7850937
J Cardiol. 2020 Jun;75(6):606-613
pubmed: 31980355
J Vet Intern Med. 2019 Mar;33(2):363-382
pubmed: 30806496
Res Vet Sci. 1995 Sep;59(2):172-5
pubmed: 8525110
J Vet Intern Med. 2020 Mar;34(2):600-606
pubmed: 32112596
Vet Surg. 2010 Aug;39(6):674-9
pubmed: 20459489
J Vet Cardiol. 2019 Dec;26:51-62
pubmed: 31809955
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320966445
pubmed: 33084480
J Thorac Cardiovasc Surg. 2011 Sep;142(3):641-9
pubmed: 21277588
Hypertension. 1996 Sep;28(3):472-7
pubmed: 8794835
J Am Coll Cardiol. 2019 Aug 6;74(5):631-641
pubmed: 31370954
J Am Vet Med Assoc. 2021 Nov 01;259(11):1332-1336
pubmed: 34727063
Clin Cardiol. 2010 Oct;33(10):630-637
pubmed: 20960538
J Vet Intern Med. 2020 Jan;34(1):53-64
pubmed: 31769114